Repeat correction tested across three patient lines
Three patient-derived lines each have an edited counterpart, linking repeat excision to reversal of the expression and receptor-function phenotypes.
↳ Figures 1, 5–6
Mutations in C9ORF72 are the most common cause of familial amyotrophic lateral sclerosis (ALS). Here, through a combination of RNA-Seq and electrophysiological studies on induced pluripotent stem cell (iPSC)-derived motor neurons (MNs), we show that increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity. These deficits are not found in iPSC-derived cortical neurons and are abolished by CRISPR/Cas9-mediated correction of the C9ORF72 repeat expansion in MNs. We also demonstrate that MN-specific dysregulation of AMPAR expression is also present in C9ORF72 patient post-mortem material. We therefore present multiple lines of evidence for the specific upregulation of GluA1 subunits in human mutant C9ORF72 MNs that could lead to a potential pathogenic excitotoxic mechanism in ALS.
increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity.
GluA1-specific causation is not isolated by receptor-blocking pharmacology or the edited-line comparisons
mutant C9ORF72 cortical neurons possess predominantly Ca2+-impermeable AMPARs, indicating that mutant C9ORF72-dependent increases in Ca2+-permeable AMPARs are selective to MNs.
the cortical comparison uses one patient line and does not test cortical excitotoxic vulnerability
[Excitotoxicity vulnerability] is abolished by CRISPR/Cas9-mediated correction of the C9ORF72 repeat expansion in MNs.
rescue across three patient-line pairs is constrained by one selected clone per line and concurrent wild-type allele editing
AMPAR expression is also selectively dysregulated in spinal cord, but not cortical, post-mortem tissue from patients harboring C9ORF72 repeat expansions.
patient-level tissue measurements support the regional association in only three patients and three controls
Derived from the full evaluation — not a separate score.
Strengths
Three patient-derived lines each have an edited counterpart, linking repeat excision to reversal of the expression and receptor-function phenotypes.
↳ Figures 1, 5–6
RNA measurements, protein measurements, receptor physiology, and antagonist-sensitive cell death connect the C9ORF72 phenotype to persistent Ca2+-permeable AMPAR function.
↳ Figures 4–6
The Discussion addresses intact GluA2 editing, differences between neuron-only and mixed cultures, and possible contributions from PICK1-dependent receptor trafficking.
↳ Figure 5d; Discussion
Limitations
JTX tests Ca2+-permeable AMPAR involvement rather than GluA1 specifically. The abstract also claims selective vulnerability without a cortical excitotoxicity comparison, extending beyond the receptor measurements in one cortical patient line.
↳ Abstract; Figure 6; Results, cortical-neuron comparison; Discussion
Figure 6 distinguishes recorded cells from differentiations but does not state which enters the ANOVA. Uncorrected Fisher's LSD in expression and cytotoxicity analyses adds uncertainty across the multi-line comparisons.
↳ Figures 5a and 6b,d,f; Methods, Data analysis
Manual transcript counting uses two independent neuropathologists, but blinded assessment is not reported. The comparison includes only three patients and three controls, limiting precision.
↳ Figure 7; Methods, Human post-mortem tissue analysis
The edited-line comparisons and complementary molecular, physiological, and pharmacological measurements support a C9ORF72-associated AMPAR phenotype. They do not identify GluA1 upregulation as the unique cause of the functional changes, because JTX blocks Ca2+-permeable receptors generally and the Discussion identifies alternative trafficking mechanisms. Unspecified analysis units and uncorrected multiple comparisons constrain the experimental assessment, while the abstract's selective-vulnerability wording exceeds the single-line cortical receptor comparison. The Discussion nevertheless provides substantive engagement with competing ALS mechanisms and appropriately distinguishes post-mortem association from causation.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
The advance is the linked molecular and functional AMPAR phenotype across patient-derived and edited motor-neuron lines. It meaningfully extends earlier excitotoxicity findings rather than establishing that phenomenon for the first time.
Three edited patient-line pairs and converging assays support the receptor phenotype, but the experiments do not isolate GluA1-specific causation. Unspecified inferential units, incomplete antibody validation reporting, and unreported blinded tissue scoring add uncertainty.
The sequence from editing to expression, physiology, toxicity, and tissue observations is readable. The headline causal and selective-vulnerability wording exceeds what those comparisons establish, and Figure 5 mislabels one significance result.
The Discussion engages competing GluA2-editing, receptor-trafficking, and neuron–glia explanations and distinguishes post-mortem association from causation. It does not fully carry the restricted cortical comparison and editing-design limitations into the specificity interpretation.
Caveats4 of 4 checks
The Results name RNAscope whereas the tissue Methods name BaseScope reagents. This is a reporting clarification rather than an established problem with the underlying measurements.
Ethics approval: declared · Data availability: declared
72 of 74 checkable references verified
74 references in manuscript
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
The mechanism is pinned down under controlled laboratory conditions in iPSC-derived neurons with isogenic CRISPR correction, plus correlative post-mortem confirmation, but nothing is shown working in vivo.
The paper presents its findings as elucidating a possible pathogenic mechanism in ALS, with no stated real-world use of the findings beyond further mechanistic understanding and research.
Drug developers and ALS trialists could act on these findings by developing and testing Ca2+-permeable AMPAR blockers as neuroprotective therapies for C9ORF72 ALS patients.
The mechanism is shown only in cultured iPSC-derived neurons and post-mortem tissue, with no in vivo or clinical evidence that blocking Ca2+-permeable AMPARs slows motor neuron loss in patients.
Evaluated 16 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Stavrou, Heffernan, Carter, et al. · 2026 · Basic medicine
human-induced pluripotent stem-cell-derived astrocytes carrying the C9ORF72 mutation disrupt mitochondrial axonal transport and mitochondrial function in cocultured motor neurons (MNs)
SupportedKasper, Lehto, Jürs, et al. · 2026 · Clinical medicine
CSF p-tau and total-tau levels were strongly associated with domain-specific cognitive performance.
TentativeCopley, Mauna, Danielson, et al. · 2026 · Basic medicine
These short RNAs engage and stabilize the TDP-43 RNA recognition motifs, which allosterically destabilizes a conserved helical region in the prion-like domain, thereby promoting aggregation-resistant conformers.
Supported